BRAF and metastatic neoplasm: NICE guidance regarding eligibility for vemurafenib in BRAF V600 mutated melanoma stipulates that patients have metastatic disease, but not all patients tested met this criterion, accounting for some of the discrepancy between actionable mutations and subsequent changes to patient management.